GlycoMimetics Q3 cash $49.4M; uproleselan Phase 3 topline by Q2 2024; NDA filing by end 2024

CRESCENT BIOPHARMA, INC.

2023-Q3 EPS reported -$0.44

Cash and cash equivalents $49.4M as of Sep 30, 2023; no revenue reported (pre-revenue biotech).
Pivotal Phase 3 uproleselan topline results on track for end of Q2 2024; NDA filing expected by end 2024.
Phase 1a GMI-1687 initial results expected by end of Q1 2024 as potential sickle cell disease treatment.
R&D expenses $5.3M (up from $4.9M) driven by GMI-1687 trial; G&A expenses $4.5M (up from $3.8M).
Updated uproleselan data in secondary AML to be presented at ASH December 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CRESCENT BIOPHARMA, INC. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the third quarter ended September 30, 2023.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

CRESCENT BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-017507

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.